Wells Fargo raised the firm’s price target on Sarepta (SRPT) to $50 from $48 and keeps an Overweight rating on the shares. Following a few eventful weeks and the preannounced quarterly results, the firm reiterates its confidence in the ELEVIDYS franchise given what Wells sees as an intact benefit-risk for ambulatory patients and potential upside from future updates on the non- ambulatory side.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sell Rating Issued for Sarepta Therapeutics Amid Uncertain Revenue Prospects and High Future Expenses
- Sarepta Therapeutics: Strong Financial Performance and Growth Potential Drive Buy Rating
- Sarepta Therapeutics Reports Strong Revenue Growth Amid Strategic Investments
- Sarepta Therapeutics: Hold Rating Amid Financial Gains and Clinical Uncertainties
- Sarepta reports Q2 adjusted EPS $2.02, consensus $1.16